Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GALR2 | O43603 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21989034 | 0.88 | SLC9A1 (0.52) | SLC9A1NPSR1POLBALDH1A1LMNA | |
| SCHEMBL3915677 | 0.87 | SLC9A1 (0.51) | SLC9A1NPSR1POLBALDH1A1LMNA | |
| SCHEMBL8513944 | 0.85 | MAPT (0.55) | SLC9A1NPSR1POLBALDH1A1LMNA | |
| SCHEMBL6492987 | 0.84 | LMNA (0.53) | SLC9A1NPSR1POLBALDH1A1LMNA | |
| SCHEMBL27796244 | 0.83 | SLC9A1 (0.56) | SLC9A1NPSR1POLBALDH1A1LMNA | |
| SCHEMBL863876 | 0.81 | SLC9A1 (0.53) | SLC9A1NPSR1POLBALDH1A1LMNA | |
| SCHEMBL11252461 | 0.79 | MAPT (0.50) | SLC9A1NPSR1POLBALDH1A1LMNA | |
| SCHEMBL6167927 | 0.79 | MAPT (0.50) | SLC9A1NPSR1POLBALDH1A1LMNA | |
| SCHEMBL8611539 | 0.79 | SLC9A1 (0.64) | SLC9A1NPSR1POLBALDH1A1LMNA | |
| SCHEMBL7375343 | 0.78 | SLC9A1 (0.61) | SLC9A1NPSR1POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504414-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080009493-A1 | Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines | ARIENTI KRISTEN L | 2008-01-10 | — | — | US | disclosed |
| US-7271261-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1435947-B1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-¬4,5|-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO MCNEIL PHARM INC (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1435947-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHOMCNEIL PHARMACEUTICAL, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003032984-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDSI/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO-MCNEIL PHARMACEUTICAL,INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009493-A1 | Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines | CDKN1A, DDB1, TMBIM6 | SLC9A1 2931/4885NPSR1 1746/4885POLB 2111/4885 |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDK4, TMBIM6, CDS2 | SLC9A1 3376/4885NPSR1 1426/4885POLB 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.